BWA
HRMY icon

Basecamp Wealth Advisors’s Harmony Biosciences HRMY Stock Holding History

Basecamp Wealth Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28K Buy
90
+20
+29% +$631 ﹤0.01% 1260
2026
Q1 		$1.96K Buy
+70
New +$2.29K ﹤0.01% 1405

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's HRMY Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Harmony Biosciences (HRMY) stake by 29% in Q2 2026, buying an estimated $631 and bringing the position to 90 shares worth $3.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Basecamp Wealth Advisors first reported a position in HRMY in Q1 2026 and has held it in 2 quarters since. 326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Basecamp Wealth Advisors held 90 shares of Harmony Biosciences worth $3.28K as of Q2 2026.
  • Basecamp Wealth Advisors bought 20 Harmony Biosciences shares in Q2 2026, an estimated $631.
  • Harmony Biosciences made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1260 holding.
  • Basecamp Wealth Advisors first reported a position in Harmony Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.